Iovance Biotherapeutics Inc
999 Skyway Rd Ste 150
Phone: (650) 260-7120p:650 260-7120 SAN CARLOS, CA  94070-2724  United States Ticker: IOVAIOVA

Wall Street Analysts bearish on Iovance Biotherapeutics

October 16 -- Street rating agencies had an overall negative view on Iovance Biotherapeutics (IOVA -10.6%) with Wells Fargo downgrading to Equal Weight from Overweight ($49 -> $29); Barclays ($45 -> $36) and HC Wainwright ($48 -> $46) lowered the target.

While Chardan Capital reaffirmed its Buy rating, it lowered target to $50 from $53.

Wells Fargo analyst Jim Birchenough says that with lack of agreement on assays to adequately characterize tumor infiltrating lymphocyte therapeutics, and unclear guidance from FDA, he sees significant risk ahead to timelines for review and approval of lifileucel, and other TIL therapeutics.

In the absence of specific FDA guidance, Birchenough sees "extended uncertainty" and would advise a "wait-and-see approach" to future regulatory discussions and progress towards agreement on TIL therapeutic characterization.

Barclays analyst Peter Lawson lowered PT after the company held a Type B meeting with the FDA and could not reach an agreement on the required potency assays for lifileucel.

Analyst "nudged back" commercialization across the entire pipeline to acid test the model. Further, based upon the uncertainty around the appropriate fix for the assay, "and out of abundance of caution," Lawson lowered the probability across the entire pipeline; nonetheless, he still likes the risk/reward on shares of Iovance.

H.C. Wainwright analyst Joseph Pantginis lowered target stating that the company's inability to reach an agreement with the FDA regarding the required potency assays to fully define the TIL therapy a bit of a bump. However, he believes Iovance's thesis remains intact and strong.

Related Businesses
- - Customer

Copyright © 2020 by (Ticker: CRMZ®). All rights reserved.  You are not permitted to use this report or the information contained herein for any purpose not expressly permitted by, Inc. Except as expressly permitted by, Inc., you are not permitted, in whole or in part, to copy, alter, correct, adapt, translate, enhance, lease, sell, sublicense, assign, distribute, publish, otherwise make available to any third party, or prepare derivative works or improvements of this report or any of the information contained therein. You are not permitted to reverse engineer, disassemble, decompile, decode, or adapt the software, algorithms or other processes used to prepare this report, or otherwise attempt to derive or gain access to the source code of same. You agree not to remove, alter, obscure, combine or otherwise change any disclaimers, trademarks, copyrights, other intellectual property rights, proprietary rights, or other symbols, notices, marks, or serial numbers on or relating to any copy of the report or on marketing or other materials that, Inc. may provide to you. You will not use this report in any manner or for any purpose that infringes, misappropriates, or otherwise violates any right of any party, or that violates any applicable law.  
The FRISK® scores, agency ratings, credit limit recommendations and other scores, analysis and commentary are opinions of, Inc. and/or its suppliers, not statements of fact, and should be one of several factors in making credit decisions.  Any reliance you place on the information in this report is strictly at your own risk. Except as expressly provided by, Inc., no warranties or representations of any type, including without limitation of results to be obtained, merchantability or fitness for a particular purpose, are made concerning any part of, Inc.’s service, including without limitation the FRISK® scores.  The information published above has been obtained from sources CreditRiskMonitor considers to be reliable., Inc. and its third-party suppliers do not guarantee or validate the accuracy and completeness of the information provided in this report, the underlying information input to create the FRISK® scores, and specifically do not assume responsibility for not reporting any information omitted or withheld.  By using this website, you accept the Terms of Use Agreement
Contact Us: 845.230.3000
Fundamental financial data concerning public companies may be provided by Refinitiv (click for restrictions)
Tuesday, October 27, 2020